Oxycodone Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Short-acting, Long-acting); By Dosage Form; By Distribution Channel; By Region; Segment Forecast, 2024- 2032
- Published Date:Jan-2024
- Pages: 118
- Format: PDF
- Report ID: PM4347
- Base Year: 2023
- Historical Data: 2019 – 2022
Report Outlook
Oxycodone drugs market size was valued at USD 5.19 billion in 2023. The market is anticipated to grow from USD 5.46 billion in 2024 to USD 8.29 billion by 2032, exhibiting a CAGR of 5.4% during the forecast period.
Market Overview
The growing burden of chronic pain diseases such as cancer, rheumatoid arthritis, lower back pain, and fibromyalgia is the key contributor for the oxycodone market growth. Certain lifestyle changes such as smoking, drinking, being obese, and low physical activity levels can increase the risk of chronic pain diseases. The demand for oxycodone drugs is increasing owing to the inability shown by other medicines to treat chronic pain. Moreover, the growing focus of market players towards the development of more efficient oxycodone drugs will fuel the market growth in the upcoming years.
- For instance, according to Clinicaltrials.gov, companies such as Pfizer, Pain Therapeutics, Kalyra Pharmaceuticals, Inc. have their oxycodone drugs in Phase 1 of the clinical trials.
However, the addictive nature of oxycodone drugs is one of the major factors limiting its growth. Moreover, the side effects associated with the use of these drugs including constipation, drowsiness, nausea, and vomiting will negatively impact the market growth. Furthermore, the opioid crisis, which is marked by a spike in the number of opioid-related mortalities and addiction cases, has prompted more regulatory interventions and actions. These actions include prescribing standards and stringent regulations on the manufacturing & distribution of oxycodone. Additionally, the drug recalls and lawsuits against the companies will also hamper the market growth in the projected years.
To Understand More About this Research: Request a Free Sample Report
Growth Factors
Rising incidence of chronic pain is expected to support the oxycodone market expansion
Oxycodone is an opioid medication which is recommended for the treatment of chronic pain diseases. Lower back pain, cancer pain, and arthritis are the most common chronic pain diseases across the world. For instance, according to an estimate by the Arthritis Foundation (AF), the global prevalence of rheumatoid arthritis (RA) is 0.5 to 1% in developed countries. The pain experienced by the most of the patients suffering from arthritis is severe which cannot be treated with other medications. The management of such pain is possible with the help of oxycodone drugs and hence, these drugs are changing the pattern of prescription in the world. Moreover, growing number of surgical procedures and increasing use of oxycodone drugs for the management of post-operative pain is expected to contribute to the market growth.
Increasing expenses for oxycodone drugs will provide a long-term opportunity for the market growth
The opioid medications have gained significant popularity among the healthcare professionals owing to their ability to manage the severe pain. This has stimulated the manufacturers to increase the R&D and marketing expenses for their oxycodone drugs. For instance, according to the annual report 2022, the advertising and product promotion costs of Collegium Pharmaceutical increased to USD 11,743.0 in 2022, from USD 4,186.0 in 2021. Moreover, the safety and effectiveness associated with the oxycodone drugs over other opioids is expected to attract practitioners, leading to an increased number of prescriptions. Furthermore, ongoing clinical trials of several pharmaceutical companies will provide a long-term opportunity for the oxycodone drugs market expansion.
Restraining Factors
Several risks of oxycodone coupled with strict regulations is expected to hamper the market growth
The use of oxycodone medications presents serious risks including opioid use disorder and overdose. Moreover, misuse and addiction of oxycodone is also impacting its demand negatively. For instance, according to the data published by the National Safety Council, in the U.S., the number of people died from preventable opioid overdoses of oxycodone increased to 12,126 in 2021, from 11,884 in 2020. Such increase in overdoses of oxycodone has also led to an increased guidelines and regulations. According to the new guidelines released by the Centers for Disease Control & Prevention (CDC) in November 2022, opioids should not be considered first-line therapy for pain management.
Report Segmentation
The market is primarily segmented based on drug type, dosage form, distribution channel, and region.
|
By Drug Type |
By Dosage Form |
By Distribution Channel |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Drug Type Insights
Long-acting segment accounted for the largest market share in 2023
The long-acting segment held the largest market share in 2022. The large share of this segment is owing to the benefits including improved compliance and convenience of less-frequent dosing intervals. Moreover, in recent years, long-acting oxycodone formulations have shown promising results among the patients suffering from severe chronic pain, which has increased its demand. Long-acting oxycodone is intended to give continuous pain relief, usually for a duration of 12 to 24 hours. This longer duration of action contributes to a more consistent blood concentration of the drug, which improves pain management and reduces variations in pain intensity. Such benefits associated with the use of long-acting formulations will drive the segmental growth throughout the forecast period.
By Dosage Form Insights
The capsules segment is expected to witness significant growth in the coming years
The capsules segment is expected to register the highest CAGR during the forecast timeframe. The high growth is owing to the advent of extended-release capsules coupled with the high prevalence of severe pain among adults. Moreover, the benefits associated with the capsules coupled with the strong sales revenue achieved by market players for their oxycodone capsules are expected to drive the segmental growth during the forecast timeframe. For instance, according to the annual report 2022, Collegium Pharmaceutical’s Xtampza ER capsules generated a revenue of USD 138.8 million in 2022, compared to USD 103.7 million in 2021. Furthermore, large prescriber base for the capsules will also fuel the segmental growth.
By Distribution Channel Insights
Hospital pharmacy segment accounted for the largest share in 2023
The hospital pharmacy segment accounted for the largest market share in 2023. The segmental growth is being driven by an increase in hospital admissions for the treatment of chronic pain and rising number of prescriptions of oxycodone. Moreover, the collaborative environment between caregiver and patient provided by hospital pharmacies to deliver comprehensive care also contributes to the segmental growth. The chronic pain having a greater degree of complexity such as post-operative pain, cancer pain, and arthritis pain need better and timely care, which increases the demand for hospital pharmacy. Furthermore, an increasing number of surgical procedures performed in hospitals coupled with the presence of large patient pool suffering from post-operative pain will drive the segmental growth.
Regional Insights
North America region held the largest market share in 2023
North America oxycodone drugs market accounted for the largest share globally. The share is attributed to the increased acceptance of oxycodone medicines as pain relievers and rising incidence of chronic illnesses. Moreover, factors such as strong presence of key market players and large volume of oxycodone prescriptions by practitioners in the U.S. are driving the oxycodone market growth in the region.
- For instance, according to the annual report 2022 of Collegium Pharmaceutical, in 2021, there were approximately 2.2 million prescriptions written for extended-release oxycodone in the U.S.
Moreover, less complications associated with the use of oxycodone over other opioid medications is expected to increase the research & development activities thereby, spurring the market growth in this region.
Asia Pacific region is anticipated to expand at a significant CAGR in the projected years
The market in Asia Pacific region is expected to witness significant growth during the forecast period. The growth is attributed to the factors such as rising number of surgical procedures, increasing need of oxycodone for the severe post-operative care, and growing burden of chronic pain diseases. For instance, as per the news article published by Hindustan Times in October 2022, every year approximately 14% of Indians seek medical attention for arthritis. Moreover, strong physical presence of the market players in the region will significantly contribute to the demand for oxycodone market. For instance, Mundipharma International has its offices in the countries including China, Japan, New Zealand, Philippines, Singapore, and Taiwan.
Key Market Players & Competitive Insights
The generic versions of the oxycodone drugs will increase the competitive rivalry in the upcoming years
The oxycodone drugs market competition is intense owing to the dominance of several major players. Factors that affect the competition in the oxycodone market includes the degree of abuse deterrence of various products as well as their cost, tolerability, and safety profiles. Furthermore, strategic initiatives such as research & development activities, new product development, and acquisitions are also responsible for the competitive environment in the market.
Some of the major players operating in the global market include:
- Acura Pharmaceuticals (U.S.)
- Alvogen (U.S.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Ascent Pharmaceuticals, Inc. (U.S.)
- Collegium Pharmaceutical (U.S.)
- Endo International plc (Ireland)
- Epic Pharma, LLC. (U.S.)
- Mallinckrodt (Ireland)
- Mundipharma International (UK)
- Pfizer Inc. (U.S.)
- Protega Pharmaceuticals Inc. (U.S.)
- Rhodes Pharmaceuticals L.P. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
Recent Developments in the Industry
- In July 2022, Protega Pharmaceuticals LLC introduced RoxyBond (oxycodone) immediate-release (IR) tablets to the US market. The opioid agonist RoxyBond is used for the treatment of severe pain which is not manageable with other therapies.
Report Coverage
The oxycodone drugs market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, drug type, dosage form, distribution channel, and their futuristic growth opportunities.
Oxycodone Drugs Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 5.46 billion |
|
Revenue forecast in 2032 |
USD 8.29 billion |
|
CAGR |
5.4% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments covered |
|
|
Regional scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
FAQ's
Oxycodone Drugs Market Size Worth $8.29 Billion By 2032
Key players in the market are Collegium Pharmaceutical, Mundipharma International
North America contribute notably towards the global Oxycodone Drugs Market
Oxycodone drugs market exhibiting the CAGR of 5.4% during the forecast period.
The Oxycodone Drugs Market report covering key segments are drug type, dosage form, distribution channel, and region.
